Company profile: Kate Therapeutics
1.1 - Company Overview
Company description
- Provider of AAV-based gene therapies targeting genetically defined muscle and heart diseases, supported by the DELIVER capsid engineering platform for evolving tissue-targeted AAV variants, MyoAAV muscle-tropic capsids for skeletal and cardiac delivery, and cargo technologies to enhance regulation, targeting, and safety.
Products and services
- Gene therapies for muscle and heart diseases: AAV-based therapies that treat genetically defined muscle and heart conditions by improving tissue-specific delivery and gene regulation via innovative platform technologies
- MyoAAV capsids: Muscle-tropic AAV capsids developed for enhanced delivery to skeletal and cardiac tissues, supporting targeted gene delivery to muscle and heart
- DELIVER capsid engineering platform: Technology platform that evolves AAV capsid variants for targeted gene delivery to specific tissues, improving tissue-specific delivery and enabling better gene regulation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Kate Therapeutics
Rocket Pharmaceuticals
HQ: United States
Website
- Description: Provider of gene therapies for rare childhood disorders, developing lentiviral and AAV vector-based programs including RP-L102 for Fanconi Anemia, RP-L301 for Pyruvate Kinase Deficiency, an AAV program for Danon Disease, and gene therapies for LAD-I, PKP2 arrhythmogenic cardiomyopathy, and BAG3-associated dilated cardiomyopathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rocket Pharmaceuticals company profile →
Nanogenics
HQ: United Kingdom
Website
- Description: Provider of research-based biotechnology developing artificial viruses for gene therapy. Products include LipTide, a synthetic peptide nanoparticle that mimics natural viruses for targeted RNA delivery to various cell types with low toxicity and repeat dosing, and ECP-105, a glaucoma therapy enhancing trabeculectomy by increasing bleb survival and reducing scarring with a single administration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nanogenics company profile →
NanoOnc
HQ: United States
Website
- Description: Provider of proprietary offerings, currently expanding operations in Madison, Wisconsin.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoOnc company profile →
Cardior Pharmaceuticals
HQ: Germany
Website
- Description: Provider of non-coding RNA-based therapeutics and related tools for heart disease, including CDR132L (Phase 2) to halt and reverse cardiac remodeling after myocardial infarction; clinical trials in heart failure and MI; the CardiorHealth miR-132 PCR kit to measure circulating miR-132; and an H19 gene therapy approach targeting cardiac hypertrophy and heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cardior Pharmaceuticals company profile →
SalioGen
HQ: United States
Website
- Description: Provider of non-viral Gene Coding technology enabling precise integration of large or multiple whole genes without double-strand breaks or guide RNA, and of programs including SGT-1001 for Stargardt disease, one-time genetic medicines for cystic fibrosis, CAR-T cell engineering for cancer and autoimmune diseases with tissue-specific integration, and therapies for inherited retinal diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SalioGen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Kate Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Kate Therapeutics
2.2 - Growth funds investing in similar companies to Kate Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Kate Therapeutics
4.2 - Public trading comparable groups for Kate Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →